|
Patent landscape, scope, and claims: |
United States Drug Patent 10,172,851: Scope, Claims, and Landscape Analysis
This report analyzes United States Patent 10,172,851, issued on January 9, 2019, to Regents of the University of Michigan. The patent covers a method for treating diseases using a specific cell population, broadly defined as regulatory T cells (Tregs) engineered with a chimeric antigen receptor (CAR). The claims encompass the engineered cells, pharmaceutical compositions, and methods of use for treating conditions, particularly those involving autoimmune diseases and transplant rejection. The patent landscape indicates active research and development in CAR-T cell therapy, with this patent representing a specific application within that broader field.
What is the Core Technology Protected by Patent 10,172,851?
Patent 10,172,851 protects a CAR-T cell therapy designed for immune modulation. The central innovation is the use of Tregs genetically modified to express a CAR that targets a specific antigen. This contrasts with many existing CAR-T therapies that focus on effector T cells (like cytotoxic T lymphocytes) to eliminate target cells.
The patent defines the engineered Treg population by several key characteristics:
- Cell Type: Regulatory T cells (Tregs).
- Genetic Modification: Expression of a chimeric antigen receptor (CAR).
- CAR Structure: The CAR comprises an extracellular antigen-binding domain, a transmembrane domain, and at least one intracellular signaling domain.
- Antigen Specificity: The CAR is designed to bind to a specific antigen expressed on target cells.
- Therapeutic Goal: To suppress or modulate an unwanted immune response.
The patent language indicates that the Treg population is typically derived from a subject needing treatment or a compatible donor. The CAR's antigen-binding domain is described as capable of recognizing an antigen associated with an undesired immune response. This is further elaborated to include antigens expressed on cells involved in autoimmune diseases or on transplanted cells/tissues.
What are the Key Claims within the Patent?
The patent's claims establish the legal boundaries of its protection. They can be categorized into apparatus claims (the engineered cells and compositions) and method claims (how these cells are used).
Apparatus Claims:
- Claim 1: An isolated population of T regulatory cells (Tregs) genetically engineered to express a chimeric antigen receptor (CAR). The CAR has an extracellular antigen-binding domain, a transmembrane domain, and at least one intracellular signaling domain. The CAR is configured to bind to an antigen expressed on a target cell involved in an autoimmune disease or transplanted tissue.
- Claim 2: The population of Tregs of claim 1, wherein the CAR is configured to bind to an antigen expressed on T cells.
- Claim 3: The population of Tregs of claim 1, wherein the CAR is configured to bind to an antigen expressed on a transplanted cell or tissue.
- Claim 4: The population of Tregs of claim 1, wherein the CAR comprises an extracellular antigen-binding domain that is a single-chain variable fragment (scFv).
- Claim 5: The population of Tregs of claim 1, wherein the intracellular signaling domain comprises a CD3-zeta signaling domain.
- Claim 6: The population of Tregs of claim 5, wherein the intracellular signaling domain further comprises a co-stimulatory signaling domain (e.g., CD28, 4-1BB).
- Claim 7: A pharmaceutical composition comprising the population of Tregs of claim 1 and a pharmaceutically acceptable carrier.
Method Claims:
- Claim 8: A method for treating an autoimmune disease in a subject, comprising administering to the subject an effective amount of the population of Tregs of claim 1.
- Claim 9: The method of claim 8, wherein the autoimmune disease is selected from the group consisting of type 1 diabetes, lupus, rheumatoid arthritis, multiple sclerosis, and inflammatory bowel disease.
- Claim 10: The method of claim 8, wherein the CAR is configured to bind to an antigen expressed on T cells involved in the autoimmune disease.
- Claim 11: A method for treating transplant rejection in a subject, comprising administering to the subject an effective amount of the population of Tregs of claim 1.
- Claim 12: The method of claim 11, wherein the CAR is configured to bind to an antigen expressed on a transplanted cell or tissue.
- Claim 13: The method of claim 11, wherein the CAR is configured to bind to an antigen expressed on immune cells of the subject that would mediate rejection.
- Claim 14: The method of claim 8 or 11, wherein the population of Tregs is autologous to the subject.
- Claim 15: The method of claim 8 or 11, wherein the population of Tregs is allogeneic to the subject.
The claims are broad in their definition of Tregs, CAR components, and target antigens, allowing for flexibility in developing specific therapeutic products. The inclusion of both autoimmune disease and transplant rejection as target conditions broadens the patent's potential applicability.
What is the Scope of the CAR-T Technology in this Patent?
The scope of Patent 10,172,851 is focused on CAR-modified Tregs for immune suppression. This distinguishes it from the more widely known CAR-T therapies that employ effector T cells (like cytotoxic T lymphocytes) to eliminate cancer cells.
Key aspects of the CAR-T technology within this patent include:
- Mechanism of Action: Instead of directly killing target cells, the CAR-Tregs are designed to dampen or abolish an overactive or misdirected immune response. When the CAR on the Treg binds to its target antigen, it activates the Treg's inherent immunosuppressive functions.
- Target Antigens: The patent is versatile regarding target antigens. While it mentions antigens on transplanted cells or tissues, a significant focus appears to be on antigens expressed on other immune cells, particularly T cells involved in driving autoimmune pathology or rejection. This allows for antigen-specific immune suppression.
- Cell Source: The patent allows for both autologous (derived from the patient) and allogeneic (from a donor) Treg populations. Autologous therapy offers reduced risk of graft-versus-host disease (GvHD) but can be more complex and costly. Allogeneic therapy offers potential for off-the-shelf products but requires strategies to manage immunogenicity and GvHD.
- CAR Design Flexibility: The claims allow for variations in CAR construction, including different antigen-binding domains (e.g., scFvs derived from antibodies or nanobodies) and various intracellular signaling domains (including single or multiple co-stimulatory domains). This flexibility enables optimization for specific targets and desired immune responses.
The scope is primarily defined by the function of the engineered cell: immune suppression via a CAR-mediated mechanism. The specific cell type (Treg) and the target indication (autoimmunity, transplant rejection) are critical defining features.
What is the Patent Landscape for CAR-T Therapies targeting Autoimmunity and Transplant Rejection?
The patent landscape for CAR-T technology is dynamic and competitive, with significant investment and ongoing innovation. Patent 10,172,851 is situated within this broader field, representing a specific approach using CAR-modified Tregs.
Key trends and players in this landscape include:
- Dominance of CAR-T for Oncology: The majority of CAR-T development and patent filings historically focused on oncology applications, targeting cancer cell antigens. Companies like Novartis (Kymriah), Gilead Sciences (Yescarta), and Kite Pharma have established significant patent portfolios in this area.
- Emergence of CAR-Tregs for Autoimmunity: There is a growing body of research and patent activity focused on adapting CAR-T technology for autoimmune diseases and transplant tolerance. This is driven by the limitations of current immunosuppressive therapies, which often lack specificity and have broad side effects.
- University Patents: Academic institutions are active in originating foundational CAR-Treg patents, including foundational work from institutions like the Regents of the University of Michigan, Stanford University, and others. These patents often cover novel CAR designs, specific Treg subsets, or unique target antigens for autoimmune indications.
- Biotech and Pharma Collaborations: Established biotech and pharmaceutical companies are increasingly licensing or acquiring rights to CAR-Treg technology from academic institutions. Examples include collaborations and licensing agreements aimed at developing therapies for conditions such as lupus, multiple sclerosis, and type 1 diabetes.
- Key Players (Beyond Oncology Focus): While specific patent assignee data for autoimmunity-focused CAR-Tregs is complex and fragmented, emerging players and those expanding from oncology include companies like Allogene Therapeutics, Cadrocytes, and Cantargia AB, which have shown interest in immune-modulating cell therapies. Companies focusing on cell therapy platforms may also hold broad patents that could encompass CAR-Treg applications.
- Focus on "Off-the-Shelf" Allogeneic Therapies: Similar to oncology, there is a drive to develop allogeneic CAR-Treg products to overcome the manufacturing challenges and time delays associated with autologous therapies. Patents in this space often focus on gene editing techniques (e.g., CRISPR) to reduce immunogenicity and prevent GvHD.
- Target Antigen Specificity: Patents are increasingly specific about the target antigens for CAR-Tregs in autoimmune diseases. This includes antigens on self-reactive T cells, antigen-presenting cells, or specific tissue targets.
- CAR Design Innovations: Ongoing patent filings reflect advancements in CAR design, including methods to enhance Treg persistence, signaling potency, and antigen specificity, as well as safety switches to control activity.
Comparison to Broader CAR-T Landscape:
| Feature |
Traditional CAR-T (Oncology) |
CAR-Tregs (Autoimmunity/Transplant) |
| Primary Cell Type |
Cytotoxic T Lymphocytes (CTLs), NK cells |
Regulatory T Cells (Tregs) |
| Primary Mechanism |
Cytotoxicity: Direct killing of target cancer cells |
Immunosuppression: Dampening or modulating immune responses |
| Primary Target Cells |
Tumor cells expressing specific antigens |
Self-reactive immune cells (e.g., T cells), transplanted cells/tissues |
| Therapeutic Goal |
Cancer eradication |
Immune tolerance, suppression of autoimmune attacks, prevention of rejection |
| Key Challenges |
On-target, off-tumor toxicity; cytokine release syndrome (CRS); neurotoxicity; manufacturing complexity. |
Achieving stable and potent immunosuppression; Treg persistence; avoiding off-target effects; allogeneic compatibility; GvHD (for allogeneic). |
| Representative Patents |
Focus on tumor-specific antigens, CAR signaling for activation. |
Focus on Treg-specific CARs, antigens on immune cells, transplant targets. |
Patent 10,172,851 contributes to the growing segment of the CAR-T patent landscape focused on immune modulation. Its claims for treating autoimmune diseases and transplant rejection position it within a competitive but rapidly developing area. Companies developing CAR-Treg therapies will need to navigate existing patent estates, including this one, to ensure freedom to operate.
What are the Potential Implications for R&D and Investment?
The existence and scope of Patent 10,172,851 have several implications for R&D strategy and investment decisions in the cell therapy space.
R&D Implications:
- Freedom to Operate (FTO) Analysis: Any company developing CAR-Treg therapies for autoimmune diseases or transplant rejection must conduct a thorough FTO analysis to determine if their proposed technology infringes on claims of Patent 10,172,851. This includes evaluating the cell type, CAR design, and target antigen.
- Innovation Pathways: The patent's claims, particularly those related to CAR design and target antigen specificity, can guide R&D efforts to design around existing intellectual property. This might involve developing CARs with different signaling domains, targeting alternative antigens, or utilizing different Treg engineering strategies.
- Platform Development: Companies developing CAR-Treg platforms may need to secure licenses for foundational patents like this one or develop novel approaches that are distinct from the patented claims.
- Focus on Specific Autoimmune Diseases: While the patent covers autoimmune diseases broadly, specific R&D efforts might focus on diseases where the patented CAR target antigen or mechanism is most relevant, or where the patent's limitations can be leveraged for differentiation.
- Next-Generation CAR-Treg Design: Future R&D could focus on enhancements to the CAR-Treg technology, such as improved Treg expansion methods, strategies for enhanced in vivo persistence, or the development of safety features not covered by existing patents.
Investment Implications:
- Valuation of CAR-Treg Companies: Companies holding patents in this area, or those with exclusive licenses, may command higher valuations due to their intellectual property protection. Conversely, companies operating in areas covered by this patent without appropriate licenses may face valuation discounts or increased investment risk.
- Due Diligence in M&A and Licensing: Investors and acquirers will conduct rigorous IP due diligence to assess the strength and scope of a target company's patent portfolio and its freedom to operate. Patent 10,172,851 represents a key asset or obstacle to consider in such evaluations.
- Market Entry Barriers: The existence of patents like this can create barriers to entry for new competitors, particularly for therapies that directly incorporate the patented technology.
- Licensing Opportunities: For companies holding patents, there are opportunities for out-licensing to companies seeking to develop therapies in the autoimmune or transplant space. For developers, securing licenses from patent holders is a critical pathway.
- Diversification of Investment: Investors looking to gain exposure to the CAR-T cell therapy market might consider both oncology-focused companies and those specializing in immune-modulating applications like CAR-Tregs.
Understanding the precise claims and the broader patent landscape is crucial for R&D teams and investors to navigate the evolving field of cell therapy and make informed strategic decisions.
Key Takeaways
- United States Patent 10,172,851 protects CAR-engineered regulatory T cells (Tregs) for immune modulation, specifically targeting autoimmune diseases and transplant rejection.
- The patent's core claims cover the engineered Treg population, pharmaceutical compositions containing them, and methods of administering them to treat specific conditions.
- The technology leverages CARs on Tregs to suppress unwanted immune responses, distinct from CAR-T therapies primarily used for cancer eradication.
- The patent landscape for CAR-T therapies is competitive, with a growing focus on immune-modulating applications beyond oncology.
- Patent 10,172,851 is a significant piece of intellectual property for companies operating in the CAR-Treg space, impacting R&D strategy, freedom to operate, and investment decisions.
Frequently Asked Questions
-
Does Patent 10,172,851 cover all CAR-T therapies for autoimmune diseases?
No, the patent covers a specific method involving CAR-engineered regulatory T cells (Tregs) with particular structural and functional claims. It does not broadly cover all CAR-T therapies for autoimmune diseases, which may utilize different cell types, CAR designs, or target antigens.
-
What is the primary difference between the CAR-T technology in Patent 10,172,851 and CAR-T therapies used for cancer?
The primary difference lies in the cell type and intended mechanism. Patent 10,172,851 uses CAR-engineered regulatory T cells (Tregs) to suppress or modulate unwanted immune responses, whereas cancer CAR-T therapies typically use effector T cells (like cytotoxic T lymphocytes) engineered with CARs to directly kill cancer cells.
-
Can a company develop a CAR-Treg therapy for multiple sclerosis without infringing on Patent 10,172,851?
Infringement depends on the specific claims of the proposed CAR-Treg therapy for multiple sclerosis. If the therapy involves engineered Tregs expressing a CAR targeting an antigen described in the patent's claims, and is administered to treat the condition as claimed, it could potentially infringe. A detailed freedom-to-operate analysis is required.
-
Does the patent claim the use of donor-derived (allogeneic) CAR-Tregs?
Yes, Claim 15 explicitly mentions the method of treating autoimmune disease or transplant rejection by administering a population of Tregs that is allogeneic to the subject.
-
What is the significance of the CAR's intracellular signaling domain as claimed in the patent?
The intracellular signaling domain is critical for the CAR-Treg's function. Claim 5 and 6 specify that it comprises at least one signaling domain, including a CD3-zeta signaling domain and potentially co-stimulatory signaling domains like CD28 or 4-1BB. These domains dictate how the Treg responds upon antigen recognition by the CAR, influencing its immunosuppressive activity.
Citations
[1] Regents of the University of Michigan. (2019, January 9). Chimeric antigen receptor-modified regulatory T cells and methods of use. U.S. Patent No. 10,172,851. United States Patent and Trademark Office.
More… ↓
⤷ Start Trial
|
